Evolva Holding
Market Cap
CHF228.9m
Last Updated
2020/07/07 20:54 UTC
Data Sources
Company Financials +
Executive Summary
Evolva Holding SA discovers, develops, and commercializes ingredients for use in food, nutrition, personal healthcare, agriculture, and other sectors in Switzerland, the United States, and internationally.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with limited growth.
Similar Companies
Share Price & News
How has Evolva Holding's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EVE's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
24.3%
EVE
0.9%
CH Chemicals
1.5%
CH Market
1 Year Return
43.0%
EVE
21.7%
CH Chemicals
1.8%
CH Market
Return vs Industry: EVE exceeded the Swiss Chemicals industry which returned 20.2% over the past year.
Return vs Market: EVE exceeded the Swiss Market which returned 1.7% over the past year.
Shareholder returns
| EVE | Industry | Market | |
|---|---|---|---|
| 7 Day | 24.3% | 0.9% | 1.5% |
| 30 Day | 28.5% | 4.2% | 0.3% |
| 90 Day | 49.1% | 15.8% | 7.9% |
| 1 Year | 43.0%43.0% | 25.7%21.7% | 5.3%1.8% |
| 3 Year | -30.4%-41.6% | 49.0%34.9% | 22.2%9.5% |
| 5 Year | -78.1%-82.7% | 101.5%71.6% | 29.9%8.1% |
Price Volatility Vs. Market
How volatile is Evolva Holding's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
We're Hopeful That Evolva Holding (VTX:EVE) Will Use Its Cash Wisely2 months ago | Simply Wall St
Introducing Evolva Holding (VTX:EVE), The Stock That Tanked 86%3 months ago | Simply Wall St
Evolva Holding SA (VTX:EVE) Analysts Just Cut Their EPS Forecasts By 17%Valuation
Is Evolva Holding undervalued compared to its fair value and its price relative to the market?
1.29x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EVE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EVE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EVE is unprofitable, so we can't compare its PE Ratio to the Chemicals industry average.
PE vs Market: EVE is unprofitable, so we can't compare its PE Ratio to the Swiss market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EVE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EVE is good value based on its PB Ratio (1.3x) compared to the CH Chemicals industry average (4.4x).
Next Steps
Future Growth
How is Evolva Holding forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
29.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EVE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EVE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EVE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EVE's revenue (24% per year) is forecast to grow faster than the Swiss market (2.3% per year).
High Growth Revenue: EVE's revenue (24% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EVE is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Evolva Holding performed over the past 5 years?
1.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EVE is currently unprofitable.
Growing Profit Margin: EVE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EVE is unprofitable, but has reduced losses over the past 5 years at a rate of 1.2% per year.
Accelerating Growth: Unable to compare EVE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EVE is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (10.1%).
Return on Equity
High ROE: EVE has a negative Return on Equity (-12.54%), as it is currently unprofitable.
Next Steps
Financial Health
How is Evolva Holding's financial position?
Financial Position Analysis
Short Term Liabilities: EVE's short term assets (CHF48.7M) exceed its short term liabilities (CHF12.3M).
Long Term Liabilities: EVE's short term assets (CHF48.7M) exceed its long term liabilities (CHF7.2M).
Debt to Equity History and Analysis
Debt Level: EVE is debt free.
Reducing Debt: EVE has no debt compared to 5 years ago when its debt to equity ratio was 2%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EVE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: EVE has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 8.5% each year.
Next Steps
Dividend
What is Evolva Holding current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EVE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EVE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EVE's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.0yrs
Average management tenure
CEO
Oliver Walker (51yo)
2yrs
Tenure
CHF914,200
Compensation
Mr. Oliver Walker has been Chief Executive Officer of Evolva Holding SA since July 10, 2018. Mr. Walker serves as Director of Kuros Biosciences AG since June 14, 2018. He served as the Chief Financial Offi ...
CEO Compensation Analysis
Compensation vs Market: Oliver's total compensation ($USD971.18K) is about average for companies of similar size in the Swiss market ($USD835.18K).
Compensation vs Earnings: Oliver's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 2yrs | CHF914.20k | no data | |
| Chief Financial Officer | 0.50yr | no data | no data | |
| COO & Chief Commercial Officer | 2yrs | no data | no data | |
| Head of Investor & Corporate Relations | no data | no data | no data | |
| Head of Legal & Compliance and Secretary of the Board | no data | no data | no data | |
| COO of Products | no data | no data | no data | |
| Head of Finance | 3.5yrs | no data | no data | |
| Head of Research & Development | 2.5yrs | no data | no data | |
| Head of Health Ingredients | 0.83yr | no data | no data | |
| Head of Supply Chain & Operations | 0.58yr | no data | no data |
2.0yrs
Average Tenure
49yo
Average Age
Experienced Management: EVE's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 0.25yr | no data | no data | |
| Director | 0.25yr | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 4.92yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 0.25yr | no data | no data |
0.3yrs
Average Tenure
65yo
Average Age
Experienced Board: EVE's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.2%.
Top Shareholders
Company Information
Evolva Holding SA's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Evolva Holding SA
- Ticker: EVE
- Exchange: SWX
- Founded: 2004
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: CHF228.897m
- Shares outstanding: 800.34m
- Website: https://www.evolva.com
Number of Employees
Location
- Evolva Holding SA
- Duggingerstrasse 23
- Reinach
- Basel-Landschaft
- 4153
- Switzerland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| EVE | SWX (SIX Swiss Exchange) | Yes | Common Shares | CH | CHF | Sep 2009 |
| ADF | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Sep 2009 |
| ELVA.F | OTCPK (Pink Sheets LLC) | Yes | Common Shares | US | USD | Sep 2009 |
| 0QQJ | LSE (London Stock Exchange) | Yes | Common Shares | GB | CHF | Sep 2009 |
| ELVA.Y | OTCPK (Pink Sheets LLC) | SPONSORED ADR | US | USD | Feb 2014 |
Biography
Evolva Holding SA discovers, develops, and commercializes ingredients for use in food, nutrition, personal healthcare, agriculture, and other sectors in Switzerland, the United States, and internationally. It offers branded ingredients, such as Veri-te Resveratrol, a natural ingredient in grapes, as well as other plants, including peanuts, cranberries, and Japanese knotweed for use in age-related health conditions; Nootkashield for pest control applications; EverSweet Stevia, a sweetener use in food, beverages, and table-top sweeteners; EveNootkatone, an ingredient for flavour and fragrance applications; and EveValencene, a citrus flavor. The company also develops and sells own products. It serves the nutrition, flavors and fragrances, animal health, personal care, and pharmaceutical markets. The company was founded in 2004 and is headquartered in Reinach, Switzerla.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/07 20:54 |
| End of Day Share Price | 2020/07/07 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.